Hers Health, Inc. Reports Second Quarter 2026 Financial Results
Hims & Hers Health shares fall despite a raised revenue forecast as a larger-than-expected quarterly loss dominates financial coverage.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent financial reporting from outlets including Reuters, Barrons.com, Investor's Business Daily, TradingView, the Wall Street Journal, Yahoo Finance, and official investor relations channels details the second quarter 2026 financial results for Hims & Hers Health, Inc., traded on the New York Stock Exchange under the ticker symbol HIMS. According to the coverage, the company reported second-quarter results that included a swing to a quarterly loss alongside a bigger-than-expected loss figure that surprised financial observers. At the same time, the company boosted its full-year revenue target and raised its forward revenue forecast for the period. Despite the upward revision to the company revenue target, financial coverage heavily emphasizes the immediate negative market reaction to the larger-than-expected second-quarter loss.
Reports from Barrons.com and Investor's Business Daily note that Hims stock fell and tumbled following the earnings release, as market participants weighed the heavier-than-anticipated losses more heavily than the improved guidance. Reuters and the Wall Street Journal highlight that the stronger-than-expected quarterly loss completely overshadowed the positive news regarding the revenue forecast raise, leaving the stock price under considerable downward pressure immediately after the announcement. Context provided across the reporting indicates that market attention had been closely focused on the company performance metrics heading into the second-quarter report. TradingView articles published ahead of and alongside the results outlined what market participants needed to look for regarding the company trajectory on the New York Stock Exchange.
The juxtaposition between exceeding certain baseline expectations and posting a surprisingly stout financial loss created a complex narrative for investors assessing the underlying health of the business operations during the second quarter of the calendar year 2026. As the market digests the newly released financial data and the revised revenue targets, coverage does not yet specify exact operational drivers behind the unexpected loss or outline precise remediation steps from management. Observers will be watching to see how the company balances its aggressive revenue growth strategies against the profitability pressures that resulted in the second-quarter loss. Future reports from corporate investor relations and financial media outlets will likely track whether the increased revenue guidance translates into bottom-line improvements in subsequent quarters.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 96d ago.
Quick answers
What were the main financial results reported by Hims & Hers Health for the second quarter of 2026?
The company reported a swing to a second-quarter loss with a bigger-than-expected deficit, alongside an increased revenue target and raised guidance.
How did the stock market react to the second-quarter earnings report?
Hims stock fell and tumbled on the New York Stock Exchange as the larger-than-expected loss overshadowed the positive revenue forecast raise.
Which news sources and outlets covered the Q2 2026 financial results?
Coverage came from Reuters, barrons.com, Investor's Business Daily, TradingView, WSJ, Yahoo Finance, and official HIMS investor relations.
Coverage (8)
- HIMS Falls 6% After Hours On Q2 Loss— Eyes Oral Testosterone And Peptides Expansion Yahoo Finance · 97d ago
- Hims & Hers bigger-than-expected quarterly loss overshadows revenue forecast raise Reuters · 97d ago
- Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough. barrons.com · 97d ago
- Hims Tumbles On Surprisingly Stout Losses Investor's Business Daily · 97d ago
- Hims & Hers Health Earnings: What To Look For From HIMS TradingView · 97d ago
- Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss WSJ · 97d ago
- Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops Yahoo Finance · 97d ago
- Hers Health, Inc. Reports Second Quarter 2026 Financial Results HIMS investor relations · 97d ago
Topics
Related trends
Cerebras surges 17% after beating on quarterly revenue and announcing Microsoft deal
Cerebras shares jump 17% after the AI chipmaker beats Q3 revenue estimates, raises its full-year forecast, and unveils a strategic Microsoft cloud partnership.
Five US states join FTC suit against Hims & Hers over privacy practices
Five U.S. states joined the FTC's lawsuit against Hims & Hers on Tuesday, expanding a case that alleges the telehealth company shared sensitive health data with Meta and Snap and charged for prescriptions before provider consultations.
CoreWeave Earnings Beat Expectations, Assuaging Market Nervousness
CoreWeave's robust earnings beat market expectations, sparking a broader AI cloud stock rally and easing debt concerns.
CoreWeave beats on revenue and lifts guidance, easing AI slowdown concerns
CoreWeave beat Q3 revenue estimates and raised its full-year forecast, sending shares up over 7% in extended trading.
The Trade Desk Jumps 8% Ahead of Earnings; Magnite Gains 2%, AppLovin Dips
The Trade Desk shares rose 8% to $14 ahead of its Q3 2026 earnings report, while Magnite gained 2% and AppLovin dipped 1% after their own results.
Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.